Hospital for Special Surgery United States

Dr Giorgio Perino
Pathologist dealing with rheumatic diseases, osteoarthritis, and inflammatory reaction to implants 

Hospital for special surgery United States

HSS is nationally ranked #1 in orthopedics, and #3 in rheumatology by U.S.News & World Report (2015-16). HSS has been top-ranked for both orthopedics and rheumatology for the 24 consecutive years.

Because an infection can be a devastating outcome for an orthopedic patient, Hospital for Special Surgery takes infection control extremely seriously and is proud of the recognition received for our significantly low infection rates

HSS and a complement of physicians within each specialty area accepts most major insurance plans. Our Insurance Advisory Service can answer questions regarding your insurance coverage.

Dr rupali joshi
research therapist 

Hospital for Special Surgery United States

Rahul Remanan
LinkedIn logo Research 

Hospital for Special Surgery United States

Best Hospital, Best Results

HSS is nationally ranked #1 in orthopedics, and #3 in rheumatology by U.S.News & World Report (2015-16). HSS has been top-ranked for both orthopedics and rheumatology for the 24 consecutive years.

Because an infection can be a devastating outcome for an orthopedic patient, Hospital for Special Surgery takes infection control extremely seriously and is proud of the recognition received for our significantly low infection rates

HSS and a complement of physicians within each specialty area accepts most major insurance plans. Our Insurance Advisory Service can answer questions regarding your insurance coverage.

Dr Sergei Rudchenko
Director-Scientist 

Humana United States

Website:
humana.com
Paulette Daniel
Consultant, Human Capital 

HYBRIGENICS France

HYBRIGENICS Hybrigenics is a biopharmaceutical company involved in the discovery and the development of new anticancer drugs. Industry sectors Biotech Therapeutics Area Oncology
Your innovative solution

Hybrigenics is developing inecalcitol, a vitamin D receptor agonist, characterized by enhanced activities against cancer cell proliferation and much reduced toxicity on blood calcium levels as compared to calcitriol, the active form of vitamin D. Therefore, inecalcitol can be given at high daily oral doses which exert cytostatic effects on tumors. 

Which problem are you solving ?

Acute myeloid leukemia (AML) has the worse prognosis of all types of leukemias (<25% 5-year survival). Furthermore, elderly or frail AML patients cannot support standard induction chemotherapy and are eligible only to treatment with either decitabine or azacytidine, two hypo-methylating agents. The goal is to increase overall survival of these desperate patients by adding daily oral inecalcitol to hypo-methylating therapy.

Target market segments

Pharmaceutical products / anticancer agents / hematological malignancies / small chemical drugs /

Key value proposition

Orphan drug status already granted for AML in US and EU / Excellent tolerance in patients / convenient daily oral dosing favoring compliance / Strong proof of principle in animal AML models

RĂ©mi DELANSORNE
CEO 

I Sonic Medical France

i Sonic Medical Makers of Next Generation non Contact Tonometers for glaucoma monitoring Industry sectors Medtech Therapeutics Area Ophthalmology
Your innovative solution

Vibration tonometry enables smart tonometers to measure eye pressure without contact,for ophthalmologists, refractive surgeons , otpicians and optometrists and self monitoring at home.

Which problem are you solving ?

Vibration tonometers measure eye pressure independently of corneal thickness and even in people with thin corneas or after refractive surgery

Target market segments

1 Ophthalmologists/ 2 Refractive Surgeons/ 3 opticians & Optometrists/ 4 people with glaucoma or at risk

Key value proposition

1 Fast Repeated measures/ 2 Works on Thin Cornea/3 Measures Corneal elasticity/4 Works after refrtactive surgery

Website:
NULL
Pierre BITOUN
NULL 

i2a France

i2a Founded over 25 years ago, i2a develops microbiology instruments, software, reagents and consumables. i2a is now launching a Total Bacteriology Lab Automation solution. Industry sectors Medtech Therapeutics Area Immunology
Infectious Diseases - Vaccines
Ivd / Diagnostics
Your innovative solution

i2a is a company working on microbiology automation. The objective is to offer a global solution from the arrival of samples to the final results. i2a manufactures and sells pre-analytical device, automatic incubator automatic reader-incubator, software, reagents and consumables. The current total bacteriology automation proposed by i2a strengthens quality, optimizes sample flow, enhances flexibility and reduces costs.

Which problem are you solving ?

Each clinical microbiology laboratory is unique and its organization may vary, but they all have seen a 10 

Target market segments

Market segment 1: Hospital Clinical Lab of Microbiology Market segment 2: Reference Lab of Microbiology Market segment 3: Small and Medium Private Lab of Microbiology

Key value proposition

Advantage 1: Strenghten quality Advantage 2: Enhance flexibility Advantage 3: Optimize sample flow Advantage 4: Reduce costs

Christian Curel
CEO & Founder 

Icahn School of Medicine at Mount Sinai United States

The Icahn School of Medicine at Mount Sinai is an international leader in medical and scientific training, biomedical research, and patient care. It is the medical school for the Mount Sinai Health System, which includes seven hospital campuses, and has more than 5,000 faculty and nearly 2,000 students, residents and fellows. Our unwavering pursuit of intellectual exchange, breakthrough research, and multidisciplinary teamwork propels us ever forward in biomedical discoveries and advances. We pursue ideas that often challenge conventional wisdom to revolutionize the practice of medicine and produce dramatically better outcomes for patients. We make big, bold bets by investing in radical free thinkers and technology at the cutting edge.

Dr Maria New
Pediatric Endocrinologist 

Icahn School of Medicine at Mount Sinai United States

Professor John He
Chief of Nephrology